Evidence map›Paper›PMID 41096703›Full record

ArticleInternational journal of molecular sciences2025

The Impact of IFN-γ Licensing on Mesenchymal Stromal Cells' Mediated Immunoregulation and HLA Class II Expression: Emerging Evidence from In Vitro Results.

Panagiotis Mallis, Theofanis Chatzistamatiou, Evangelia Gkatzoflia, Hava Zdrava, Eirini-Faidra Sarri, Efstathios Michalopoulos, Alexandros Spyridonidis, Catherine Stavropoulos-Giokas

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Panagiotis MallisHellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, 115 27 Athens, Greece.ORCID 0000-0001-9429-190X
Theofanis ChatzistamatiouHistocompatibiliy and Immunogenetics Lab, Biomedical Research Foundation Academy of Athens, 115 27 Athens, Greece.ORCID 0000-0003-4895-0155
Evangelia GkatzofliaHellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, 115 27 Athens, Greece.
Hava ZdravaHellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, 115 27 Athens, Greece.
Eirini-Faidra SarriHellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, 115 27 Athens, Greece.
Efstathios MichalopoulosHellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, 115 27 Athens, Greece.ORCID 0000-0002-1901-6294
Alexandros SpyridonidisHellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, 115 27 Athens, Greece.
Catherine Stavropoulos-GiokasHellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, 115 27 Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) exert their immunoregulatory properties after licensing by inflammatory signaling cues, e.g., interferon (IFN)-γ. However, MSCs licensing by IFN-γ may result in increased expression of human leukocyte antigen (HLA) class II, which is related to rapid cell elimination, impairment of their immunosuppressive properties, and patient sensitization. The aim of this study was to evaluate the impact of IFN-γ on mediated immunoregulation and HLA class II expression. In this study, Wharton's jelly (WJ) MSCs were isolated from human umbilical cords. Well-defined WJ-MSCs were submitted to IFN-γ exposure, and after 96 h, evaluation of biomolecule secretion and HLA class II expression was performed. Typing of HLA alleles using a next-generation sequencing (NGS) platform was performed. IFN-γ-primed WJ-MSCs secreted a high amount of immunoregulatory biomolecules, while elevated expression of HLA-DRB1 was observed. Analyses the NGS results showed the possibility of WJ-MSCs cluster formation based on their frequency of detected HLA alleles and immunoregulatory potential. Taking into consideration that IFN-γ-primed WJ-MSCs express HLA class II alleles, it is suggested that the HLA histocompatibility between allogeneic donor and recipient should be strongly considered to acquire the most beneficial outcome for the MSCs therapeutic strategy.

Indexed as

Histocompatibility Antigens Class IIInterferon-gammaMesenchymal Stem CellsCells, CulturedHumansImmunomodulationUmbilical CordWharton JellyHistocompatibility Antigens Class IIInterferon-gammaadvanced therapy medicinal productsautoimmune disordershuman leukocyte antigensinterferon-γmesenchymal stromal cells

Identifiers

PMID41096703
PMCPMC12525040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.